Crescent Ventures
Geldenaaksebaan 329, Leuven, Vlaams-Brabant, 3001, Belgium
Overview
Crescent Ventures develops and delivers dependable, secure, and environmentally friendly Internet of Things solutions for smart buildings, smart cities, industry 4.0, and smart energy applications around the world. They enable and accelerate the transition to a safer, more sustainable, and more comfortable living environment, allowing businesses to thrive.
- Total investments
- 1
- Lead investments
- 0
- Investments · 12mo
- 1
- Active investors
- 0
Investment portfolio
- Exeliom
Participated · Series A · Oct 2025
Founded in 2016, Exeliom Biosciences engineers live-bacterial, NOD2-targeting immunomodulators to boost patients’ innate immune responses. Its lead candidate, EXL01, is a Faecalibacterium prausnitzii-derived therapy that reprograms macrophages and the tumour micro-environment to overcome resistance to existing treatments. EXL01 is currently being tested in three Phase 2 oncology trials alongside immune-checkpoint inhibitors, including what the company calls the largest randomised Phase 2 study worldwide of a bacterial therapy in gastric cancer. The programme also includes a Phase 2 trial in Crohn’s disease and a study aimed at preventing recurrent Clostridioides difficile infection. Fresh capital will fund proof-of-concept Phase 2 work, preparation for a new U.S. cancer indication and broader international expansion. To date, Exeliom has secured nearly €30 million in combined dilutive and non-dilutive financing, underscoring strong investor confidence in its precision immunotherapy platform.
Team
No current team members are available.